https://www.selleckchem.com/products/sop1812.html To develop recombinant factor IX (FIX) variants with augmented clotting activity. We generated three new variants, FIX-YKALW, FIX-ALL and FIX-LLW, expressed in SK-Hep-1 cells and characterized in vitro and in vivo. FIX-YKALW showed the highest antigen expression level among the variants (2.17µg ), followed by FIX-LLW (1.5µg ) and FIX-ALL (0.9µg ). The expression level of FIX variants was two-fivefold lower than FIX-wild-type (FIX-WT) (4.37µg ). However, the biological activities of FIX variants were 15-31 times greater than FIX-WT in the chromogenic assay. Moreover, the new variants FIX-YKALW, FIX-LLW and FIX-ALL also presented higher specific activity than FIX-WT (17, 20 and 29-fold higher, respectively). FIX variants demonstrated a better clotting time than FIX-WT. In hemophilia B mice, we observed that FIX-YKALW promoted hemostatic protection. We have developed three improved FIX proteins with potential for use in protein replacement therapy for hemophilia B. We have developed three improved FIX proteins with potential for use in protein replacement therapy for hemophilia B. Primary sclerosing cholangitis (PSC) is a well-known complication of ulcerative colitis (UC), but it is rare to encounter patients requiring both living donor liver transplantation (LDLT) and proctocolectomy. We report a case of elective two-stage surgery involving proctocolectomy performed after LDLT for a patient with early colon cancer concurrent with PSC-related UC. To our knowledge, this is the first report of concurrent cancer successfully treated with both LDLT and proctocolectomy. A 32-year-old Japanese man with colon cancer associated with UC underwent restorative proctocolectomy at 3months after living donor liver transplantation (LDLT) for PSC. He was diagnosed with PSC and UC when he was a teenager. Conservative therapy was initiated to treat both PSC and UC. He had experienced recurrent cholangitis for years; therefore, a biliary